Comprehensive treatment of TCM
Phase 2Small molecule
Comprehensive treatment of TCM is one of 11 small molecule programs targeting Pelvic Inflammatory Disease. It is currently in Phase 2.
1
Indications
1
Total Trials
0
Active Trials
10
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
20 competitors in Pelvic Inflammatory Disease
#DrugCompanyPhaseTrials
1Avelox
BayerApproved
Flagyl
DDePuy Orthopaedics
Approved
Levaquin
WWim Janssens
Approved
Floxin
WWim Janssens
Phase 3
Zithromax
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Avelox
BayerPhase 3
Morinidazole
Jiangsu Hansoh Pharmaceutical Co., Ltd.Approved
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 2
Rocephin
CConrado Roberto Hoffmann Filho
Phase 2
Azithromycin IV
PfizerPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Pelvic Inflammatory Disease1 trial
Clinical Research of TCM on Pelvic Inflammatory Disease Sequelae
Unknown status·SShanghai University of Traditional Chinese Medicine·Phase 2·NCT02972151·175 enrolled
Sources
References
- [1]
- [2]
- [3]
- [4]
Details